Bon Natural Life Limited — Form 6-K Summary
Business context and reporting period
Bon Natural Life Limited is a China-based provider of natural bio-ingredient solutions for functional food, personal care, cosmetic and pharmaceutical manufacturers. Its products include fragrance compounds, health supplements and bioactive food ingredients. The filing, dated September 23, 2026, reports unaudited results for the six months ended March 31, 2026. The filing header identifies the report as being for September 2026.
Financial performance and key metrics
| Metric | Six months ended March 31, 2026 | Six months ended March 31, 2025 |
|---|---|---|
| Revenue | $8.10 million | $7.95 million |
| Gross profit | $2.19 million | $1.91 million |
| Gross margin | 27.0% | 24.0% |
| Operating income (loss) | $(8.58) million | $0.28 million |
| Net income (loss) | $(9.20) million attributable to Bon Natural Life; $(9.20) million consolidated net loss | $0.17 million attributable to Bon Natural Life; $0.14 million consolidated net income |
| Basic and diluted Class A loss per share | $1.51 loss | $0.56 and $0.50 earnings, respectively |
| Cash provided by operating activities | $6.42 million | $(4.30) million |
| Cash used in investing activities | $(4.28) million | $0.004 million provided |
| Cash provided by financing activities | $0.36 million | $12.32 million |
| Cash and restricted cash at period-end | $9.18 million, including $5.78 million cash and $3.40 million restricted cash | $8.89 million |
Revenue mix and material changes
- Total revenue increased 1.9%, or $147,965, despite a significant change in product mix.
- Fragrance compound revenue decreased 60.4% to $2.24 million, reflecting reduced demand, particularly for Perilla frutescens extract. Volume declined 40.2% to 22,448 kilograms.
- Health supplement revenue increased 2,478.4% to $1.29 million, with cases sold increasing from 6,132 to 55,000.
- Bioactive food ingredient revenue increased 104.2% to $4.57 million, driven by volume growth from 120,740 kilograms to 287,727 kilograms and the launch of a Chinese-medicine-integrated product line.
- Gross profit increased 14.6% and gross margin expanded by three percentage points, primarily because of higher gross profit from health supplements and bioactive ingredients.
- Total operating expenses increased 562.8% to $10.76 million. The principal unusual charges were a $5.66 million provision for credit losses and $1.92 million of impairment losses on advances to suppliers, neither of which occurred in the comparable period.
- The credit-loss provision included $2.57 million against accounts receivable and $3.09 million against other receivables under the CECL model.
- Selling expenses rose 500.5%, general and administrative expenses rose 36.7%, and R&D expenses rose 709.7%, partly reflecting amortization of share-based compensation and fees paid through share issuance.
Cash flow, debt and liquidity
- Operating cash flow was $6.42 million, despite the reported net loss, primarily because of non-cash credit-loss provisions, supplier-advance impairments, depreciation and amortization, and share-based compensation, together with reductions in advances to suppliers and prepaid assets.
- Investing cash outflows were $4.28 million, primarily for $4.28 million of construction-in-progress expenditures.
- Financing cash inflow was $0.36 million. Borrowings included $5.10 million of short-term loans, $0.71 million of long-term loans and $0.75 million of related-party borrowings; repayments included $5.46 million of short-term loans and $0.74 million of long-term loans.
- Interest expense increased 53.2% to $252,168, which management attributed to higher average long-term loan balances. The filing does not provide total debt balances or detailed maturity information in the supplied text.
- Cash and restricted cash increased by $2.92 million during the period. Restricted cash represented approximately $3.40 million of the reported $9.18 million balance.
Guidance, outlook, risks and unusual items
- No quantitative financial guidance was provided.
- Management is pursuing expanded sales and a new marketing strategy, while positioning the Chinese-medicine-integrated bioactive ingredient line for growth through lower introductory pricing.
- Management noted weaker customer adoption and recognition of Perilla frutescens extract, which reduced fragrance compound demand.
- The substantial credit-loss and supplier-advance impairment charges indicate heightened collectability and recoverability risks. The filing states that utilization of supplier advances was below expectation.
- Other unusual items included $57,813 of gain from disposal of the Dali subsidiary, $4.28 million of construction-in-progress spending, and share-based or share-settled fees, including $59,200 of legal fees paid through issuance of 40,000 Class A ordinary shares.
- The filing contains customary forward-looking statement warnings, including risks from competition, rapid market changes, emerging risks, customer demand, collection of receivables, financing needs and other factors that could cause actual results to differ materially.
Important facts for investors to verify
- Reconcile the reported $9.20 million attributable net loss with the consolidated net loss and review the underlying unaudited financial statements.
- Assess the nature, aging and expected recoverability of receivables subject to the $5.66 million CECL provision.
- Investigate the suppliers, terms and remaining recoverability of the $1.92 million impaired supplier advances.
- Review total short-term, long-term and related-party debt, collateral, interest rates and maturities, which are not fully stated in the supplied filing text.
- Determine the availability and restrictions governing the $3.40 million of restricted cash.
- Evaluate whether rapid growth in health supplements and bioactive ingredients can offset the continuing decline in fragrance compound demand without materially reducing pricing or margins.
- Confirm the timing and expected return of the $4.28 million construction-in-progress investment and the accounting effects of the Dali subsidiary disposal.